Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 188 clinical trials
A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL
This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …
- 0 views
- 19 Feb, 2024
- 1 location
2 march edit9
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
- 1 location
2 march upen 6
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 11
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 12
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 13
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 14
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 15
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
2 march upen 16
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024
4march upen 16
Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level and have completed at least 3 months of follow-up after the first infusion, or have discontinued early due to disease progression, initiation of a new cancer therapy, or death. This protocol …
- 0 views
- 19 Feb, 2024